CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Ketotifen 1 MGWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug1016 Growth Mindset Wiki 1.00
drug636 Control Wiki 0.38

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D001943 Breast Neoplasms NIH 0.50

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0003002 Breast carcinoma HPO 0.50

There is one clinical trial.

Clinical Trials

1 Ketotifen: Novel Use as a Cardioprotective Agent in Breast Cancer Patients Receiving Anthracycline-containing Chemotherapy as Well as the Potential Beneficial Effects of Ketotifen in the Hypothetical Management of COVID-19

The objective of our study was to evaluate the expected cardioprotective effects of ketotifen due to its activity as an iron-chelating agent previously uncovered by us in the in vitro chemical test which included in the study, when used in patients receiving anthracyclines for the treatment of breast cancer. The study was a randomized : , prospective controlled trial : , and the patients were identified by coded numbers to maintain privacy. Eligible patients (111) fulfilled the criteria. Control Group: 55 patients received their standard therapy (anthracycline-containing chemotherapy without ketotifen). Ketotifen Group: 56 patients received anthracycline-containing chemotherapy plus ketotifen as a cardioprotective agent. Ketotifen will be given orally as one tablet (1 mg/tablet) 3 times daily, before and during the chemotherapeutic cycle for 6 cycles of treatment. Blood samples were obtained from all patients, and echocardiography two times for each patient at baseline and after 6 months (EF%).

NCT04435028 Breast Cancer Iron Chelation Drug: Ketotifen 1 MG
MeSH:Breast Neoplasms
HPO:Breast carcinoma Neoplasm of the breast

Primary Outcomes

Description: the serum levels of LDH, CK-MB, troponin I, TIBC, ferritin, anti-cardiolipin IgG, and, iron were done

Measure: prophylaxis effect of Ketotifen on patient`s hearts during the treatment of anthracyclines

Time: 6 months

Related HPO nodes (Using clinical trials)

HP:0003002: Breast carcinoma
Genes 97
CHEK2 MLH1 PIK3CA RAD54L CTNNB1 MLH1 KLLN RAD51 NQO2 APC RAD50 TP53 STK11 RAD51C PHB RAD51C PTEN BRCA1 KRAS CDH1 AKT1 NTHL1 IDH2 MRE11 TWIST1 TP53 XRCC3 BARD1 ATR CHEK2 CDH1 BRIP1 POLE AKT1 BRCA1 TP53 MSH2 CDKN2A BARD1 PALLD SEC23B CDKN2A SEC23B STK11 NBN RB1CC1 BRCA2 RAD51 BRCA2 AAGAB POLD1 AKT1 TP53 RNF43 NTHL1 IDH1 COL14A1 BRCA2 CHEK2 PALB2 TP53 RAD51D WRN KRAS BRIP1 PPM1D SDHB SLC6A17 HMMR SMAD4 MSH2 MSH6 PRKN AKT1 USF3 ESR1 BRCA2 PTEN SDHC PALB2 CHEK2 PIK3CA CASP8 PIK3CA PIK3CA ATM MDM2 FGFR2 APC OPCML BRCA1 BRCA1 SLC22A18 BRCA1 PTEN SDHD PALB2
Protein Mutations 73
A289T A864V C3435T D538G D769H D769N D769Y D988Y E380Q E542K E545K E709K E757A G309A G309E G598V G776C G776V H1047R I655V I767M L536H L536P L536Q L536R L755P L755S L786V L841V L858R L861Q L869R P125A P12A P13K P187S P535H P596L R108K R222C R572Y R678Q R831C R831H R849W R896C S310F S310Y S463P S653C S768I S8814A S9313A T47D T733I T790M T798I T798M T862I V244M V534E V600E V659E V697L V742I V769M V773M V774M V777L V842I Y537C Y537N Y537S
SNP 38
rs1011970 rs10407022 rs1045485 rs10941679 rs10995190 rs11045585 rs11133360 rs11249433 rs12762549 rs13281615 rs13387042 rs16942 rs1800566 rs2002555 rs2046210 rs2237060 rs2241193 rs2297480 rs236114 rs2380205 rs271924 rs2981582 rs3803662 rs3817198 rs4073 rs4646 rs4973768 rs614367 rs6504950 rs6971 rs704010 rs7333181 rs7349683 rs889312 rs909253 rs9344 rs9457827 rs999737
HP:0100013: Neoplasm of the breast
Genes 125
CHEK2 MLH1 PIK3CA RAD54L CTNNB1 MLH1 BAP1 CDKN2A KLLN RAD51 NQO2 APC TERT RAD50 TP53 STK11 RAD51C PHB ACD PTEN RAD51C PTEN CASP10 RELA BRCA1 KRAS CDH1 AKT1 PTEN RASGRP1 CDK4 NTHL1 IDH2 MRE11 TWIST1 TP53 XRCC3 BARD1 ATR CHEK2 CDH1 GNAS BRIP1 POLE APC AKT1 BRCA1 TP53 MSH2 CDKN2A BARD1 PRLR PALLD SEC23B APC CDKN2A LMNA SEC23B STK11 NBN RB1CC1 MITF BRCA2 RAD51 BRCA2 AAGAB POLD1 AKT1 TP53 RNF43 NTHL1 IDH1 COL14A1 MC1R BRCA2 CHEK2 PALB2 MGMT TP53 RAD51D WRN C11ORF95 KRAS BRIP1 PPM1D FASLG SDHB SLC6A17 HMMR SMAD4 MSH2 PRKAR1A MSH6 PRKN AKT1 FAS USF3 ESR1 BRCA2 PTEN PTEN CDKN2B SDHC PALB2 CHEK2 PIK3CA CASP8 PIK3CA TERF2IP PIK3CA POT1 ATM MDM2 FAS FGFR2 APC OPCML PRKCD BRCA1 BRCA1 SLC22A18 BRCA1 PTEN SDHD PALB2
Protein Mutations 0
SNP 0